Ritedose Pharmaceuticals Receives FDA Approval for Generic Formoterol Fumarate Inhalation Treatment for Respiratory Illness
COLUMBIA, SC May 1, 2025 — Ritedose Pharmaceuticals, a division of The Ritedose Corporation (Ritedose), was granted approval by the US Food and Drug Administration (FDA) to manufacture and market generic formoterol fumarate inhalation solution (20 mcg/2 mL), a treatment for chronic obstructive pulmonary disease (COPD) and other respiratory ailments.
Recent Comments